BioSpace News Archive

Imagine Pharma, a biotechnology company focused on the development of its novel polypeptide (IMG-1) across three distinct platforms: Oral Delivery, Therapeutics, and Regenerative Medicine, will showcase its discovery of Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) during its oral presentation today at the American Transplant Congress being held in Boston.

Virta Health, the leader in type 2 diabetes reversal, revealed preliminary five-year results from its landmark clinical trial at the American Diabetes Association 82nd Scientific Sessions.

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a preclinical study in blood entitled “ A TCR Mimic CAR T Cell Specific for NDC80 Is Broadly Reactive With Solid Tumors and Hematological Malignancies ”.

Thermo Fisher Scientific Inc., the world leader in serving science, is providing proteomics and biopharmaceutical laboratories working in drug discovery and R&D applications with an innovative mass spectrometry solution that, for the first time, unlocks the ability to clearly decipher complex mixtures of large macromolecules.

Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues.

Median overall survival and 18-month overall survival data continue to show improvements over historical controls 1.

The company announces new mass spectrometry instruments, workflows, software and industry collaborations during ASMS 2022 Conference.

Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent high-resolution LC/MS for oligonucleotide purity analysis and sequence confirmation.

myCare-004 Study Finds Cellworks Personalized Therapy Biosimulation Provides Superior OS, DFS and TRG Predictions for GEA Patients.

myCare-024-04 Study Finds Cellworks Personalized Biosimulation Provides Superior OS and PFS Predictions for GBM Patients Beyond Standard Clinical Factors.